Abstract:Objective: Rivaroxaban is a specific factor Xa (FXa) inhibitor for venous thromboembolism treatment. Recently, increasing evidence have reported the beneficial effects of rivaroxaban on treating cardiovascular disorders such as coronary and peripheral artery disease. However, its potential influence on abdominal aortic aneurysm (AAA) remains unclear. This study aims to investigate whether rivaroxaban treatment could attenuate experimental AAA progression and its related mechanisms. Approaches and results: In human aneurysmal aorta, FXa protein expression was significantly upregulated. Further investigations identified a positive correlation among plasma FXa level, AAA severity (the maximal aortic diameter), and intra-aneurysmal thrombus percentage. In Ang II (angiotensin II)-infused ApoE-/mice, the administration of high dose rivaroxaban (15 mg/kg/d) for 14 days significantly reduced the maximal aortic diameter, while low dose rivaroxaban (5 mg/kg/d) did not display such a protective role. Although rivaroxaban treatments reduced the incidence of AAA and thrombus formation, these differences did not reach statistical significance. Immunohistochemistry revealed a pronounced aortic remodeling including increased collagen content and enhanced elastin degradation in Ang II-induced AAAs, which was inhibited by high dose rivaroxaban treatment. Further analysis demonstrated that rivaroxaban exerted its protective effects by decreasing leukocyte infiltration, inflammatory cytokines expression, and matrix metalloproteinases (MMPs) expression in the aortic wall. The inhibitory effect of rivaroxaban on aneurysm development was also observed in calcium chloride induced AAA model. Mechanistically, in human aortic endothelial cells, FXa stimulation increased the expression of inflammatory cytokines (interleukin (IL)-1 beta, IL-6, IL-8, monocyte chemoattractant protein-1) and adhesive molecules, which were all reversed by the cotreatment of rivaroxaban. Subsequent monocyte-endothelial cell interaction was enhanced after FXa stimulation and was alleviated by rivaroxaban cotreatment. In addition, FXa induced a significantly heightened expression of MMP2 in human aortic endothelial cells, which was ameliorated by rivaroxaban coadministration. Conclusions: Rivaroxaban attenuated both angiotensin IIand calcium chloride-induced abdominal aortic aneurysm (AAA) progressions, through inhibiting aortic remodeling and inflammation. Rivaroxaban could be a promising therapeutic agent in attenuating AAA development by counteracting FXa-induced aortic wall inflammation.

Inhibiting the Th17/IL-17A-related inflammatory responses with digoxin confers protection against experimental abdominal aortic aneurysm

Artesunate Attenuated the Progression of Abdominal Aortic Aneurysm in a Mouse Model

Inhibitory Effects of Doxycycline on the Onset and Progression of Abdominal Aortic Aneurysm and Its Related Mechanisms.

Increased plasma renin by vasodilators promotes the progression of abdominal aortic aneurysm

Resolvin D2/GPR18 signaling enhances monocytic myeloid-derived suppressor cell function to mitigate abdominal aortic aneurysm formation

Vitamin D Receptor Activation Reduces Angiotensin-II-Induced Dissecting Abdominal Aortic Aneurysm in Apolipoprotein E-Knockout Mice

Tributyrin Intake Attenuates Angiotensin II-Induced Abdominal Aortic Aneurysm in LDLR-/- Mice

Angiotensin-(1-7) Mitigated Angiotensin II-induced Abdominal Aortic Aneurysms in Apolipoprotein E-knockout Mice.

Dexmedetomidine Alleviates Abdominal Aortic Aneurysm by Activating Autophagy Via AMPK/mTOR Pathway

Dexmedetomidine Suppresses the Development of Abdominal Aortic Aneurysm by Downregulating the Mircorna‑21/pdcd 4 Axis.

Ginsenoside Rb1 Attenuates Angiotensin Ii-Induced Abdominal Aortic Aneurysm Through Inactivation of the Jnk and P38 Signaling Pathways

Tanshinone IIA attenuates elastase-induced AAA in rats via inhibition of MyD88-dependent TLR-4 signaling.

Combinational Therapy with Aspirin and Ticagrelor Alleviates Vascular Inflammation and Angiotensin IIdriven Abdominal Aortic Aneurysm Formation in Mice

Trehalose attenuates abdominal aortic aneurysm formation by inducing autophagy in smooth muscle cells

Inhibition of miR-188-5p Suppresses Progression of Experimental Abdominal Aortic Aneurysms

Abstract 468: HIF-1α Mediates Initiation and Progression of Experimental Abdominal Aortic Aneurysms

Recombinant leptin attenuates abdominal aortic aneurysm formation in angiotensin II-infused apolipoprotein E-deficient mice.

Inhibition of Mir-155 Attenuates Abdominal Aortic Aneurysm in Mice by Regulating Macrophage-Mediated Inflammation.

TRPV5 Attenuates Abdominal Aortic Aneurysm in Mice by Regulating KLF4-dependent Phenotype Switch of Aortic Vascular Smooth Muscle Cells.

Factor Xa Inhibitor Rivaroxaban Suppresses Experimental Abdominal Aortic Aneurysm Progression Via Attenuating Aortic Inflammation

Hypoxia-inducible factor 1 in clinical and experimental aortic aneurysm disease.